J b chemicals and pharmaceuticals Limited has submitted its quarterly compliance certificate to BSE Limited, fulfilling mandatory regulatory requirements under SEBI Depositories Regulations for the quarter ended March 31, 2026.

Regulatory Compliance Filing

The pharmaceutical company filed the certificate on April 6, 2026, in compliance with Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. The submission was made to BSE Limited at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai.

Certificate Verification

The certificate was issued by Datamatics Business Solutions Limited, which serves as the Registrar and Share Transfer Agent for J. B. Chemicals & Pharmaceuticals Limited. The certificate confirms that securities received for dematerialization have been properly processed according to regulatory requirements.

Key compliance confirmations include:

• Securities received for dematerialization have been mutilated and cancelled after due verification
• The depository's name has been substituted in records as the registered owner
• All procedures completed within the mandated 15-day period from receipt of security certificates

Corporate Structure

J. B. Chemicals & Pharmaceuticals Limited operates with its registered office in Ahmedabad, Gujarat, and corporate office in Mumbai, Maharashtra. The company is incorporated under CIN: L24390GJ1976PLC173077.

The filing was signed by Sandeep Phadnis, Vice President – Secretarial & Company Secretary, and countersigned by Satish Patil, Manager at Datamatics Business Solutions Limited. This quarterly certificate submission represents part of the company's ongoing regulatory compliance obligations with Indian securities market regulations.

J B Chemicals and Pharmaceuticals Limited has officially announced the cessation of Mr. Nikhil Chopra as Chief Executive Officer and Key Managerial Personnel, effective from the closing of business hours on March 31, 2026. The pharmaceutical company made this disclosure under Regulation 30 of the Securities and Exchange Board of India Listing Regulations on April 1, 2026.

Leadership Transition Details

The company's announcement follows an earlier intimation dated January 21, 2026, which disclosed Chopra's resignation as Whole-time Director from the conclusion of the Board meeting held on that date. However, he continued serving as CEO until March 31, 2026, ensuring a structured transition period.

Resignation Background

In his resignation letter dated January 21, 2026, Chopra outlined a phased departure approach. His resignation as Whole-time Director and member of Board committees became effective immediately upon the conclusion of the Board meeting where the letter was presented. The CEO role, however, continued until March 31, 2026, allowing for operational continuity.

Chopra cited personal reasons and the pursuit of other professional opportunities as the primary factors behind his decision. He explicitly confirmed that no other reasons contributed to his resignation beyond those stated in his letter.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of the Listing Regulations and the SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. The announcement was signed by Sandeep Phadnis, Vice President – Secretarial & Company Secretary, ensuring proper corporate governance protocols were followed.

Company Operations

J.B. Chemicals & Pharmaceuticals Limited, incorporated under CIN L24390GJ1976PLC173077, operates from its registered office in Ahmedabad, Gujarat, and corporate office in Mumbai. The company maintains its commitment to pharmaceutical operations under the tagline "Good People for Good Health" while managing this leadership transition.

In his farewell message, Chopra expressed gratitude to Board colleagues and management for their cooperation during his tenure, wishing the company success in its future endeavors. The structured approach to his departure demonstrates the company's focus on maintaining operational stability during leadership changes.